493 related articles for article (PubMed ID: 15772955)
21. Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: Subgroup analysis of two Phase III trials.
Chua DT; Ma J; Sham JS; Mai HQ; Choy DT; Hong MH; Lu TX; Au GK; Min HQ
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1300-6. PubMed ID: 16750333
[TBL] [Abstract][Full Text] [Related]
22. Association between high initial tissue levels of cyclin d1 and recurrence of nasopharyngeal carcinoma.
Lai JP; Tong CL; Hong C; Xiao JY; Tao ZD; Zhang Z; Tong WM; Betz CS
Laryngoscope; 2002 Feb; 112(2):402-8. PubMed ID: 11889405
[TBL] [Abstract][Full Text] [Related]
23. Coexpression of cyclooxygenase-2 and thymidine phosphorylase as a prognostic indicator in patients with FIGO stage IIB squamous cell carcinoma of uterine cervix treated with radiotherapy and concurrent chemotherapy.
Pyo H; Kim YB; Cho NH; Suh CO; Park TK; Yun YS; Kim GE
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):725-32. PubMed ID: 15936552
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with epidermal growth factor receptor expression.
Soo R; Putti T; Tao Q; Goh BC; Lee KH; Kwok-Seng L; Tan L; Hsieh WS
Arch Otolaryngol Head Neck Surg; 2005 Feb; 131(2):147-52. PubMed ID: 15723947
[TBL] [Abstract][Full Text] [Related]
25. Selective cyclooxygenase-2 inhibition suppresses basic fibroblast growth factor expression in human esophageal adenocarcinoma.
Baguma-Nibasheka M; Barclay C; Li AW; Geldenhuys L; Porter GA; Blay J; Casson AG; Murphy PR
Mol Carcinog; 2007 Dec; 46(12):971-80. PubMed ID: 17477358
[TBL] [Abstract][Full Text] [Related]
26. Effects of cyclooxygenase 2 inhibitors on biological traits of nasopharyngeal carcinoma cells.
Chen PY; Long QC
Acta Pharmacol Sin; 2004 Jul; 25(7):943-9. PubMed ID: 15210070
[TBL] [Abstract][Full Text] [Related]
27. Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo.
Grimes KR; Warren GW; Fang F; Xu Y; St Clair WH
Oncol Rep; 2006 Oct; 16(4):771-6. PubMed ID: 16969492
[TBL] [Abstract][Full Text] [Related]
28. Loss of p16 expression has prognostic significance in human nasopharyngeal carcinoma.
Mäkitie AA; MacMillan C; Ho J; Shi W; Lee A; O'Sullivan B; Payne D; Pintilie M; Cummings B; Waldron J; Warde P; Irish J; Brown D; Gilbert R; Gullane P; Liu FF; Kamel-Reid S
Clin Cancer Res; 2003 Jun; 9(6):2177-84. PubMed ID: 12796384
[TBL] [Abstract][Full Text] [Related]
29. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels.
Shin YK; Park JS; Kim HS; Jun HJ; Kim GE; Suh CO; Yun YS; Pyo H
Cancer Res; 2005 Oct; 65(20):9501-9. PubMed ID: 16230415
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of Survivin and Livin in nasopharyngeal carcinoma.
Xiang Y; Yao H; Wang S; Hong M; He J; Cao S; Min H; Song E; Guo X
Laryngoscope; 2006 Jan; 116(1):126-30. PubMed ID: 16481824
[TBL] [Abstract][Full Text] [Related]
31. Another way to estimate outcome of advanced nasopharyngeal carcinoma--is concurrent chemoradiotherapy adequate?
Lin JC; Liang WM; Jan JS; Jiang RS; Lin AC
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):156-64. PubMed ID: 15337551
[TBL] [Abstract][Full Text] [Related]
32. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma.
Denkert C; Winzer KJ; Müller BM; Weichert W; Pest S; Köbel M; Kristiansen G; Reles A; Siegert A; Guski H; Hauptmann S
Cancer; 2003 Jun; 97(12):2978-87. PubMed ID: 12784332
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical expression of epidermal growth factor receptor and cyclooxygenase-2 in pediatric nasopharyngeal carcinomas: no significant correlations with clinicopathological variables and treatment outcomes.
Fang FM; Li CF; Chien CY; Rau KM; Huang HY
Int J Pediatr Otorhinolaryngol; 2007 Mar; 71(3):447-55. PubMed ID: 17208308
[TBL] [Abstract][Full Text] [Related]
34. Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy.
O'Connor JK; Avent J; Lee RJ; Fischbach J; Gaffney DK
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1034-40. PubMed ID: 15001242
[TBL] [Abstract][Full Text] [Related]
35. Cyclooxygenase-2 expression in advanced nasopharyngeal carcinoma--a prognostic evaluation and correlation with hypoxia inducible factor 1alpha and vascular endothelial growth factor.
Chan CM; Ma BB; Hui EP; Wong SC; Mo FK; Leung SF; Kam MK; Chan AT
Oral Oncol; 2007 Apr; 43(4):373-8. PubMed ID: 16979927
[TBL] [Abstract][Full Text] [Related]
36. Significant anti-proliferation of human endometrial cancer cells by combined treatment with a selective COX-2 inhibitor NS398 and specific MEK inhibitor U0126.
Gao J; Niwa K; Takemura M; Sun W; Onogi K; Wu Y; Seishima M; Mori H; Tamaya T
Int J Oncol; 2005 Mar; 26(3):737-44. PubMed ID: 15703831
[TBL] [Abstract][Full Text] [Related]
37. Suppressive effect of selective cyclooxygenase-2 inhibitor on cytokine release in human neutrophils.
Kimura T; Iwase M; Kondo G; Watanabe H; Ohashi M; Ito D; Nagumo M
Int Immunopharmacol; 2003 Oct; 3(10-11):1519-28. PubMed ID: 12946449
[TBL] [Abstract][Full Text] [Related]
38. Differential cyclooxygenase-2 enzyme expression in radiosensitive versus radioresistant glioblastoma multiforme cell lines.
Karim A; McCarthy K; Jawahar A; Smith D; Willis B; Nanda A
Anticancer Res; 2005; 25(1B):675-9. PubMed ID: 15816645
[TBL] [Abstract][Full Text] [Related]
39. Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells.
Li S; Tong Q; Zhang W; Wang Q; Chen Z; Wu Q
Cancer Invest; 2008 May; 26(4):333-7. PubMed ID: 18443952
[TBL] [Abstract][Full Text] [Related]
40. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma.
Qian CN; Guo X; Cao B; Kort EJ; Lee CC; Chen J; Wang LM; Mai WY; Min HQ; Hong MH; Vande Woude GF; Resau JH; Teh BT
Cancer Res; 2002 Jan; 62(2):589-96. PubMed ID: 11809714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
